{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:46:33Z","timestamp":1787064393808,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.neulet.2016.11.007","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T12:30:48Z","timestamp":1478781048000},"page":"190-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson\u2019s disease: A meta-analysis"],"prefix":"10.1016","volume":"636","author":[{"given":"Yi","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neulet.2016.11.007_bib0005","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/fcp.12145","article-title":"Homocysteine excess: delineating the possible mechanism of neurotoxicity and depression","volume":"29","author":"Bhatia","year":"2015","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"August (4)","key":"10.1016\/j.neulet.2016.11.007_bib0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3233\/JAD-2006-9404","article-title":"Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease?","volume":"9","author":"Seshadri","year":"2006","journal-title":"J. Alzheimers Dis."},{"issue":"December (15)","key":"10.1016\/j.neulet.2016.11.007_bib0015","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1096\/fasebj.13.15.2277","article-title":"Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels","volume":"13","author":"Jakubowski","year":"1999","journal-title":"FASEB J."},{"issue":"March (5)","key":"10.1016\/j.neulet.2016.11.007_bib0020","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1471-4159.2001.00178.x","article-title":"Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways","volume":"76","author":"White","year":"2001","journal-title":"J. Neurochem."},{"issue":"August (8)","key":"10.1016\/j.neulet.2016.11.007_bib0025","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/clinchem\/44.8.1833","article-title":"Homocysteine and vitamins in cardiovascular disease","volume":"44","author":"Jacobsen","year":"1998","journal-title":"Clin. Chem."},{"issue":"December (6)","key":"10.1016\/j.neulet.2016.11.007_bib0030","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/WCO.0b013e3283168df0","article-title":"Dementia in parkinson\u2019s disease","volume":"21","author":"Aarsland","year":"2008","journal-title":"Curr. Opin. Neurol."},{"issue":"4","key":"10.1016\/j.neulet.2016.11.007_bib0035","first-page":"267","article-title":"Parkinson disease: an update","volume":"87","author":"Gazewood","year":"2013","journal-title":"Am. Fam. Phys."},{"issue":"March (1)","key":"10.1016\/j.neulet.2016.11.007_bib0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12017-012-8174-1","article-title":"Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated parkinson\u2019s disease patients","volume":"14","author":"Gorgone","year":"2012","journal-title":"Neuromol. Med."},{"issue":"July (6)","key":"10.1016\/j.neulet.2016.11.007_bib0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.parkreldis.2008.10.005","article-title":"Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson\u2019s disease patients","volume":"15","author":"Nevrly","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neulet.2016.11.007_bib0050","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/S1353-8020(08)70681-3","article-title":"Plasma homocysteine levels in idiopathic Parkinson\u2019s disease: role of idiopathic Parkinson\u2019s disease and levodopa treatment","volume":"13","author":"Ha","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"issue":"7","key":"10.1016\/j.neulet.2016.11.007_bib0055","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa011613","article-title":"Plasma homocysteine as a risk factor for dementia and Alzheimer\u2019s disease","volume":"346","author":"Seshadri","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"June (6)","key":"10.1016\/j.neulet.2016.11.007_bib0060","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease","volume":"51","author":"Gibb","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"OCtober (12)","key":"10.1016\/j.neulet.2016.11.007_bib0065","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2016.11.007_bib0070","unstructured":"Rostom A, Dube C, Cranney A, et al., Celiac Disease. Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Sep. (Evidence Reports\/Technology Assessments, No. 104.) Appendix D. Quality Assessment Forms. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK35156."},{"issue":"7414","key":"10.1016\/j.neulet.2016.11.007_bib0075","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.neulet.2016.11.007_bib0080","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.neulet.2016.11.007_bib0085","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.22522","article-title":"Homocysteine and cognitive impairment in Parkinson\u2019s disease: a biochemical, neuroimaging and genetic study","volume":"24","author":"Rodriguez-Oroz","year":"2009","journal-title":"Mov. Dis."},{"issue":"August (16)","key":"10.1016\/j.neulet.2016.11.007_bib0090","first-page":"2957","article-title":"The expression features of serum cystatin C and homocysteine of Parkinson\u2019s disease with mild cognition dysfunction","volume":"19","author":"Chen","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.neulet.2016.11.007_bib0095","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mds.22511","article-title":"Hyperhomocysteine in levodopa-treated patients with Parkinson\u2019s disease dementia","volume":"24","author":"Zoccolella","year":"2009","journal-title":"Mov. Dis."},{"key":"10.1016\/j.neulet.2016.11.007_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000338610","article-title":"The impact of MRI white matter hyperintensities on dementia in Parkinson\u2019s disease in relation to the homocysteine level and other vascular risk factors","volume":"12","author":"Slawek","year":"2013","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neulet.2016.11.007_bib0105","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.archger.2013.04.015","article-title":"Clinical significance of homocysteine on dementia in Parkinson\u2019s disease","volume":"57","author":"Song","year":"2013","journal-title":"Arch. Gerontol. Geriatr."},{"issue":"10","key":"10.1016\/j.neulet.2016.11.007_bib0110","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/FPC.0b013e32835693f7","article-title":"Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson\u2019s disease","volume":"22","author":"Bialecka","year":"2012","journal-title":"Pharmacogenetic Genom."},{"issue":"10","key":"10.1016\/j.neulet.2016.11.007_bib0115","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1515\/CCLM.2005.193","article-title":"Plasma homocysteine levels in L-dopa-treated Parkinson\u2019s disease patients with cognitive dysfunctions","volume":"43","author":"Zoccolella","year":"2005","journal-title":"Clin. Chem. Lab. Med."},{"issue":"3","key":"10.1016\/j.neulet.2016.11.007_bib0120","first-page":"231","article-title":"Correlation between cognitive dysfunction and plasma homocysteine level in patients with Parkinson\u2019s disease","volume":"14","author":"Gan","year":"2012","journal-title":"Chin. J. Geriatr. Heart Brain Vessel Dis."},{"key":"10.1016\/j.neulet.2016.11.007_bib0125","first-page":"23","article-title":"Discussion the correlation of homocysteine levels with the Parkinson\u2019s disease and its cognitive impairment","volume":"16","author":"Yu","year":"2014","journal-title":"MMJK"},{"issue":"5","key":"10.1016\/j.neulet.2016.11.007_bib0130","first-page":"525","article-title":"Relationship between high homocysteine levels in serum and cognitive impairment of patients with Parkinson\u2019s disease","volume":"10","author":"Ju","year":"2015","journal-title":"J. Chengdu Med. College"},{"issue":"5","key":"10.1016\/j.neulet.2016.11.007_bib0135","first-page":"383","article-title":"Analysis of correlation between plasma of homocysteine levels and cognitive impairment in elderly patients with Parkinson\u2019s disease","volume":"23","author":"Liu","year":"2015","journal-title":"J. Brain Nerv. Dis."},{"issue":"March (8)","key":"10.1016\/j.neulet.2016.11.007_bib0140","first-page":"123","article-title":"Plasma homocysteine changes and cognitive function of elderly with Parkinson\u2019s disease","volume":"11","author":"Niu","year":"2016","journal-title":"Chin Pract Med."},{"key":"10.1016\/j.neulet.2016.11.007_bib0145","first-page":"1","article-title":"Study on the relation of plasma homocysteine with mild cognitive impairment in Parkinson\u2019s disease, Hunan, Xiangya School of Medicine","author":"Xu","year":"2013","journal-title":"Cent. South Univ."},{"issue":"8","key":"10.1016\/j.neulet.2016.11.007_bib0150","first-page":"3","article-title":"Association between plasma homocysteine and cognitive dysfunction in patients with Parkinson\u2019s disease","volume":"12","author":"Cai","year":"2015","journal-title":"J. Chin. Prescrip. Drug."},{"issue":"October (19)","key":"10.1016\/j.neulet.2016.11.007_bib0155","first-page":"2278","article-title":"Relationship between plasma homocysteine and Parkinson\u2019s disease with dementia","volume":"40","author":"Pan","year":"2014","journal-title":"Jiangsu Med. J."},{"key":"10.1016\/j.neulet.2016.11.007_bib0160","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ane.12106","article-title":"Elevated homocysteine levels in levodopa-treated idiopathic Parkinson\u2019s disease: a meta-analysis","volume":"128","author":"Hu","year":"2013","journal-title":"Acta Neurol. Scand."},{"issue":"1\u20132","key":"10.1016\/j.neulet.2016.11.007_bib0165","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2006.05.040","article-title":"Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson\u2019s disease","volume":"404","author":"Religa","year":"2006","journal-title":"Neurosci. Lett."},{"issue":"10","key":"10.1016\/j.neulet.2016.11.007_bib0170","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.parkreldis.2010.07.012","article-title":"Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease","volume":"16","author":"Muller","year":"2010","journal-title":"Parkinsonism Related Dis."},{"issue":"June (6)","key":"10.1016\/j.neulet.2016.11.007_bib0175","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1017\/S0007114500000751","article-title":"The effect of 677CT and 1298AC mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects","volume":"83","author":"Chango","year":"2000","journal-title":"Br. J. Nutr."},{"issue":"3","key":"10.1016\/j.neulet.2016.11.007_bib0180","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11239-012-0856-x","article-title":"Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer\u2019s disease","volume":"36","author":"Cacciapuoti","year":"2013","journal-title":"J. Thromb Thrombolysis"},{"issue":"7","key":"10.1016\/j.neulet.2016.11.007_bib0185","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa011613","article-title":"Plasma homocysteine as a risk factor for dementia and Alzheimer\u2019s disease","volume":"346","author":"Seshardi","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neulet.2016.11.007_bib0190","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/mds.22227","article-title":"Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson\u2019s disease patients","volume":"24","author":"Camicioli","year":"2009","journal-title":"Mov. Disord."},{"issue":"September (9)","key":"10.1016\/j.neulet.2016.11.007_bib0195","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.tips.2011.05.003","article-title":"Is hyperhomocysteinemia an Alzheimer\u2019s disease (AD) risk factor, an AD marker or neither?","volume":"32","author":"Zhuo","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"issue":"Pt 9","key":"10.1016\/j.neulet.2016.11.007_bib0200","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1093\/brain\/awt206","article-title":"Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study","volume":"136","author":"Hooshmand","year":"2013","journal-title":"Brain: J. Neurol."},{"issue":"1","key":"10.1016\/j.neulet.2016.11.007_bib0205","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/brain\/awg006","article-title":"Homocysteine and brain atrophy on MRI of non-demented elderly","volume":"126","author":"den Heijer","year":"2003","journal-title":"Brain: J. Neurol."},{"issue":"October (10)","key":"10.1016\/j.neulet.2016.11.007_bib0210","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.20527","article-title":"A systematic review of prevalence studies of dementia in Parkinson\u2019s disease","volume":"20","author":"Aarsland","year":"2005","journal-title":"Mov. Dis."},{"issue":"28","key":"10.1016\/j.neulet.2016.11.007_bib0215","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.2174\/092986710792232012","article-title":"Hyperhomocysteinemia in levodopa treated patients with Parkinson\u2019s disease: potential implications in cognitive dysfunction and dementia?","volume":"17","author":"Zoccolella","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"12","key":"10.1016\/j.neulet.2016.11.007_bib0220","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov Dis."},{"issue":"January (1)","key":"10.1016\/j.neulet.2016.11.007_bib0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.0022-3042.2001.00676.x","article-title":"Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson\u2019s disease","volume":"80","author":"Duan","year":"2002","journal-title":"J. Neurochem."},{"issue":"September (9)","key":"10.1016\/j.neulet.2016.11.007_bib0230","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/gps.723","article-title":"Homocysteine in neuropsychiatric disorders of the elderly","volume":"17","author":"Reutens","year":"2002","journal-title":"Int. J. Geriatr. Psychiatry"}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394016308461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394016308461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T22:23:31Z","timestamp":1657664611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394016308461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":46,"alternative-id":["S0304394016308461"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2016.11.007","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson\u2019s disease: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2016.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}